289 related articles for article (PubMed ID: 33187184)
1. Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020.
Devarakonda S; Cottini F; Bumma N; Khan A; Sharma N; Chaudhry M; Benson D; Rosko A; Efebera Y
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33187184
[TBL] [Abstract][Full Text] [Related]
2. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016.
Terpos E;
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):329-339. PubMed ID: 28462890
[TBL] [Abstract][Full Text] [Related]
3. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.
Terpos E;
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386
[TBL] [Abstract][Full Text] [Related]
4. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
[TBL] [Abstract][Full Text] [Related]
5. Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020.
Du J; Zhuang J
Chronic Dis Transl Med; 2021 Dec; 7(4):220-226. PubMed ID: 34786541
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Moreau P; Attal M; Hulin C; Arnulf B; Belhadj K; Benboubker L; Béné MC; Broijl A; Caillon H; Caillot D; Corre J; Delforge M; Dejoie T; Doyen C; Facon T; Sonntag C; Fontan J; Garderet L; Jie KS; Karlin L; Kuhnowski F; Lambert J; Leleu X; Lenain P; Macro M; Mathiot C; Orsini-Piocelle F; Perrot A; Stoppa AM; van de Donk NW; Wuilleme S; Zweegman S; Kolb B; Touzeau C; Roussel M; Tiab M; Marolleau JP; Meuleman N; Vekemans MC; Westerman M; Klein SK; Levin MD; Fermand JP; Escoffre-Barbe M; Eveillard JR; Garidi R; Ahmadi T; Zhuang S; Chiu C; Pei L; de Boer C; Smith E; Deraedt W; Kampfenkel T; Schecter J; Vermeulen J; Avet-Loiseau H; Sonneveld P
Lancet; 2019 Jul; 394(10192):29-38. PubMed ID: 31171419
[TBL] [Abstract][Full Text] [Related]
7. Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016.
Tandon N; Kumar SK
Indian J Hematol Blood Transfus; 2017 Jun; 33(2):153-158. PubMed ID: 28596644
[TBL] [Abstract][Full Text] [Related]
8. Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):499-508. PubMed ID: 32376237
[TBL] [Abstract][Full Text] [Related]
9. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Holstein SA; Howard A; Avigan D; Bhutani M; Cohen AD; Costa LJ; Dhodapkar MV; Gay F; Gormley N; Green DJ; Hillengass J; Korde N; Li Z; Mailankody S; Neri P; Parekh S; Pasquini MC; Puig N; Roodman GD; Samur MK; Shah N; Shah UA; Shi Q; Spencer A; Suman VJ; Usmani SZ; McCarthy PL
Biol Blood Marrow Transplant; 2020 Oct; 26(10):e247-e255. PubMed ID: 32589921
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
11. Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials.
Hu D; Chen L; Yan D; Dong W; Chen M; Niu S; Wang S; Zhang J; Nie X; Fang Y
Front Pharmacol; 2023; 14():1149138. PubMed ID: 37408760
[No Abstract] [Full Text] [Related]
12. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H; Mai EK; Bertsch U; Fenk R; Nievergall E; Tichy D; Besemer B; Dürig J; Schroers R; von Metzler I; Hänel M; Mann C; Asemissen AM; Heilmeier B; Weinhold N; Huhn S; Kriegsmann K; Luntz SP; Holderried TAW; Trautmann-Grill K; Gezer D; Klaiber-Hakimi M; Müller M; Khandanpour C; Knauf W; Scheid C; Munder M; Geer T; Riesenberg H; Thomalla J; Hoffmann M; Raab MS; Salwender HJ; Weisel KC;
Lancet Haematol; 2022 Nov; 9(11):e810-e821. PubMed ID: 36328040
[TBL] [Abstract][Full Text] [Related]
13. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Shah N; Chari A; Scott E; Mezzi K; Usmani SZ
Leukemia; 2020 Apr; 34(4):985-1005. PubMed ID: 32055000
[TBL] [Abstract][Full Text] [Related]
14. Recent updates on CAR T clinical trials for multiple myeloma.
Lin Q; Zhao J; Song Y; Liu D
Mol Cancer; 2019 Nov; 18(1):154. PubMed ID: 31684964
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
Parikh RH; Lonial S
CA Cancer J Clin; 2023; 73(3):275-285. PubMed ID: 36627265
[TBL] [Abstract][Full Text] [Related]
17. Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost.
Suzuki K
Int J Hematol; 2020 Apr; 111(4):512-518. PubMed ID: 32125606
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials.
Xiang X; He Q; Ou Y; Wang W; Wu Y
Front Pharmacol; 2020; 11():544754. PubMed ID: 33343342
[No Abstract] [Full Text] [Related]
19. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.
Holstein SA; Bahlis N; Bergsagel PL; Bhutani M; Bolli N; Brownstein C; Demolis P; Foureau D; Gay F; Ghobrial IM; Gormley N; Hillengass J; Kaiser M; Maus MV; Melenhorst JJ; Merz M; Dwyer MO; Paiva B; Pasquini MC; Shah N; Wong SW; Usmani SZ; McCarthy PL
Transplant Cell Ther; 2021 Oct; 27(10):807-816. PubMed ID: 34107340
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of newly diagnosed multiple myeloma in transplant-eligible patients].
Sakaida E
Rinsho Ketsueki; 2020; 61(9):1306-1316. PubMed ID: 33162530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]